The current pipeline includes Androgen Restored Contraception (ARC), Estetrol (E4) and Zona Pellucida 3 Cancer (ZP3C) immunotherapy . Active ZP3 immunisation for ovarian cancer has been sold to HRA Pharma (France) in October 2014, whereas the other applications were retained by Pantarhei Bioscience (PRB). All rights on E4 have been sold to Mithra Pharmaceuticals (Belgium) in March 2015, whereas PRB has exclusively licensed back the rights on oncological and veterinary applications. The ARC pill has been licensed out to Gedeon Richter (Hungary) in January 2019 for the regions Europe, Russia, Latin America and Australia.
PRB has founded a subsidiary company Pantarhei Oncology (PRO) to develop oncological treatments with a current focus on advanced breast and prostate cancer.